Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of HD-10019 for the treatment of FLT3 mutated acute myeloid leukemia (AML)

Next Previous
Trial Profile

Study of HD-10019 for the treatment of FLT3 mutated acute myeloid leukemia (AML)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 05 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HD 10019 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions

Most Recent Events

  • 05 Feb 2024 New trial record
  • 30 Jan 2024 According to a Harmonic Discovery media release, the company is expected to commence IND-enabling studies in late 2024.
  • 30 Jan 2024 According to a Harmonic Discovery media release, the company announced an exclusive licensing agreement of a novel small-molecule drug candidate for the treatment of FLT3 mutated acute myeloid leukemia (AML) from BioVentures (University of Arkansas for Medical Sciences) and UC San Francisco (UCSF).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top